This compound is primarily utilized in the development of targeted drug delivery systems, particularly in the field of cancer therapy. Its structure allows for conjugation with various therapeutic agents, enhancing their solubility and bioavailability. The PEG4 linker improves the pharmacokinetic properties of the drug, facilitating controlled release and reducing potential side effects. Additionally, it is employed in the synthesis of antibody-drug conjugates (ADCs), where it serves as a crucial linker to attach cytotoxic drugs to monoclonal antibodies, enabling precise targeting of cancer cells. Its application extends to research in immunomodulation and anti-inflammatory therapies, leveraging its ability to modulate immune responses effectively.